351 related articles for article (PubMed ID: 25990808)
1. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.
Koskimaa HM; Paaso AE; Welters MJ; Grénman SE; Syrjänen KJ; van der Burg SH; Syrjänen SM
J Transl Med; 2014 Feb; 12():44. PubMed ID: 24524328
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative.
Koskimaa HM; Paaso A; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 Nov; 13():370. PubMed ID: 26608420
[TBL] [Abstract][Full Text] [Related]
4. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
[TBL] [Abstract][Full Text] [Related]
5. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
[TBL] [Abstract][Full Text] [Related]
6. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
7. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
[TBL] [Abstract][Full Text] [Related]
8. The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.
Koskimaa HM; Paaso A; Welters MJP; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1491-1503. PubMed ID: 28324192
[TBL] [Abstract][Full Text] [Related]
9. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.
Visser J; Nijman HW; Hoogenboom BN; Jager P; van Baarle D; Schuuring E; Abdulahad W; Miedema F; van der Zee AG; Daemen T
Clin Exp Immunol; 2007 Nov; 150(2):199-209. PubMed ID: 17937675
[TBL] [Abstract][Full Text] [Related]
10. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
Jiang B; Xue M
Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
12. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ and IL-5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa.
Paaso A; Koskimaa HM; Welters MJP; Kero K; Rautava J; Syrjänen K; van der Burg SH; Syrjänen S
Clin Exp Dent Res; 2021 Oct; 7(5):903-913. PubMed ID: 33421352
[TBL] [Abstract][Full Text] [Related]
14. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
15. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
[TBL] [Abstract][Full Text] [Related]
16. Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN).
Mathur SP; Mathur RS; Rust PF; Young RC
Am J Reprod Immunol; 2001 Oct; 46(4):280-7. PubMed ID: 11642677
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
[TBL] [Abstract][Full Text] [Related]
18. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
19. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
Nakagawa M; Stites DP; Farhat S; Sisler JR; Moss B; Kong F; Moscicki AB; Palefsky JM
J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
